[go: up one dir, main page]

KR100760875B1 - Melanin production inhibitory skin whitening cosmetic composition - Google Patents

Melanin production inhibitory skin whitening cosmetic composition Download PDF

Info

Publication number
KR100760875B1
KR100760875B1 KR1020060055757A KR20060055757A KR100760875B1 KR 100760875 B1 KR100760875 B1 KR 100760875B1 KR 1020060055757 A KR1020060055757 A KR 1020060055757A KR 20060055757 A KR20060055757 A KR 20060055757A KR 100760875 B1 KR100760875 B1 KR 100760875B1
Authority
KR
South Korea
Prior art keywords
composition
skin whitening
skin
peptide compound
gelatin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
KR1020060055757A
Other languages
Korean (ko)
Inventor
김문무
김세권
Original Assignee
부경대학교 산학협력단
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 부경대학교 산학협력단 filed Critical 부경대학교 산학협력단
Priority to KR1020060055757A priority Critical patent/KR100760875B1/en
Application granted granted Critical
Publication of KR100760875B1 publication Critical patent/KR100760875B1/en
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/64Proteins; Peptides; Derivatives or degradation products thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61QSPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00Preparations for care of the skin
    • A61Q19/02Preparations for care of the skin for chemically bleaching or whitening the skin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/74Biological properties of particular ingredients
    • A61K2800/78Enzyme modulators, e.g. Enzyme agonists
    • A61K2800/782Enzyme inhibitors; Enzyme antagonists

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Dermatology (AREA)
  • Birds (AREA)
  • Epidemiology (AREA)
  • Cosmetics (AREA)

Abstract

본 발명은 멜라닌 생성 억제 피부미백용 조성물에 관한 것으로, 이를 더욱 상세하게 설명하면, 세포내의 멜라닌 생성을 억제하여 기미, 주근깨 개선 등의 피부미백을 위하여 어류로부터 유래한 젤라틴 펩티드를 함유하는 화장품 조성물로서, 펩타이드 화합물은 분자 중에 글리신-프롤린-하이드록실프롤린 (Glycine- Proline-Hydroxyproline)의 아미노산 서열을 갖고, 아미노산 3~20개로 이루어져 있는 것을 특징으로 하며, 이는 어피 젤라틴을 효소-가수분해한 후, 분자량 4.5 kDa 이하의 범위내의 가수분해물로 부터 분리정제한 펩타이드 화합물로 피부미백효과가 탁월한 화장품 조성물에 관한 것으로, 연고, 크림, 로션, 화장수, 팩, 산제, 과립제, 정제, 캅셀제 또는 첩포제와 같은 통상적인 제형으로 제조될 수 있다. The present invention relates to a composition for inhibiting melanin production skin whitening, which will be described in more detail as a cosmetic composition containing gelatin peptides derived from fish for skin whitening such as inhibiting melanin production in the cell to improve blemishes, freckles, etc. The peptide compound has an amino acid sequence of Glycine-Proline-Hydroxyproline in the molecule, and is composed of 3 to 20 amino acids, which is obtained by enzymatic hydrolysis of fish gelatin, followed by molecular weight. The present invention relates to a cosmetic composition having excellent skin whitening effect from a peptide compound separated from hydrolyzate within the range of 4.5 kDa or less, and is commonly used as an ointment, cream, lotion, lotion, pack, powder, granule, tablet, capsule or patch. It may be prepared in a phosphorus formulation.

Description

멜라닌 생성 억제 피부미백용 화장품 조성물 {Compositions for whitening skin by inhibition of melanin synthesis} Composition for whitening skin by inhibiting melanin production {Compositions for whitening skin by inhibition of melanin synthesis}

본 발명은 멜라닌 생성 억제효과가 탁월한 젤라틴 펩티드를 함유한 피부 미백용 화장품 조성물에 관한 것으로, 더욱 상세하게는 피부 멜라노사이트 세포 활성 및 멜라닌 생합성 억제 효과가 탁월한 젤라틴 펩티드를 유효성분으로 함유하는 샴 연고, 크림, 로션, 화장수 등의 조성물을 제조하는 것을 특징으로 하며, 본 발명에 따른 펩타이드 화합물은 분자 중에 글리신-프롤린-하이드록실프롤린 (Glycine- Proline-Hydroxyproline)의 아미노산 서열을 갖고, 아미노산 9 - 16개로 이루어져 있는 것을 특징으로 하며, 상기 제조방법은 어피 젤라틴을 효소-가수분해한 후, 분자량 4.5 kDa 이하의 가수분해물로부터 분리정제한 펩타이드 화합물이다.The present invention relates to a cosmetic composition for skin whitening containing a gelatin peptide excellent in inhibiting melanin production, and more specifically, to a siamese ointment containing a gelatin peptide excellent in inhibiting skin melanocyte cell activity and melanin biosynthesis as an active ingredient, It is characterized by preparing a composition such as cream, lotion, lotion, the peptide compound according to the invention has an amino acid sequence of glycine-proline-hydroxyproline (Glycine- Proline-Hydroxyproline) in the molecule, 9-16 amino acids It is characterized in that, the production method is a peptide compound separated and purified from hydrolyzate having a molecular weight of 4.5 kDa or less after the enzyme-hydrolysis of fish gelatin.

사람의 피부색은 피부 내부의 멜라닌(melanin) 농도와 분포에 따라 결정되는데, 유전적인 요인 외에도, 태양 자외선이나 피로, 스트레스 등의 환경적 또는 생리적 조건에 의해서도 영향을 받는다. 멜라닌은 아미노산의 일종인 티로신(tyrosine)에 티로시나제(tyrosinase)라는 효소가 작용하여 도파(DOPA), 도파퀴논(Dopaquinone)으로 바뀐 후 비효소적인 산화반응을 거쳐 만들어진다. 그러나, 멜 라닌이 만들어지는 경로는 알려져 있지만, 티로시나제가 작용하는 이전 단계인 멜라닌 합성을 유도하는 메카니즘(mechanism)이 무엇인지에 대해서는 아직도 자세히 밝혀지지 않고 있다. 이와 같은 멜라닌의 합성이 피부 내에서 과도하게 일어나면, 피부 톤을 어둡게 하고, 기미, 주근깨 등을 발생시키기기도 한다. 따라서, 피부내의 멜라닌 색소의 합성을 저해시키면, 피부 톤을 밝게 하여 피부 미백을 실현할 수 있을 뿐만 아니라 자외선, 호르몬 및 유전적인 원인에 기인하여 발생하는 기미, 주근깨 등의 피부 과색소 침착증을 개선시킬 수 있다. 따라서, 종래에는 하이드로퀴논(hydroquinone)이나 아스콜빈산(ascorbic acid), 코지산(kojic acid), 글루타티온(glutathione)과 같은 티로시나제에 대해 저해 활성을 갖는 물질을 연고, 에센스 등의 화장료에 배합하므로써 피부 미백을 실현하거나, 기미, 주근깨 등의 피부 과색소 침착증을 개선하였다. 그러나, 하이드로퀴논은 소정의 미백효과를 발휘하지만, 피부 자극성이 심하여 배합량을 극소량으로 제한해야 하는 문제점이 있고, 아스콜빈산은 산화되기 쉬워 이를 배합한 화장료는 변색, 변취되는 등의 문제가 발생하는 단점이 있다. 또한, 글루타티온, 시스테인 등의 티올계 화합물은 특유의 불쾌한 냄새를 가질 뿐만 아니라 경피흡수에도 문제점이 있고, 이들의 배당체 및 유도체들도 극성이 높으므로 화장료의 배합 성분으로 사용하기는 어렵다. 한편, 태반 추출물 등은 피부에 자극이 없으나, 미백 효과가 불충분하다.Human skin color is determined by the concentration and distribution of melanin in the skin. In addition to genetic factors, it is also influenced by environmental or physiological conditions such as ultraviolet rays, fatigue and stress. Melanin is a type of amino acid tyrosine (tyrosinase) acts as a tyrosinase enzyme (tyrosinase) acts to convert to dopa (DOPA), dopaquinone (Dopaquinone) is produced through a non-enzymatic oxidation reaction. However, although the pathway by which melanin is made is known, it is still not clear what mechanisms induce melanin synthesis, the previous step in which tyrosinase works. When such synthesis of melanin occurs excessively in the skin, it may darken the skin tone, and may cause spots and freckles. Therefore, by inhibiting the synthesis of melanin pigment in the skin, not only can brighten the skin tone to realize skin whitening, but also improve skin hyperpigmentation such as spots, freckles, etc. caused by ultraviolet rays, hormones and genetic causes. have. Therefore, conventionally, a substance having an inhibitory activity against tyrosinase, such as hydroquinone, ascorbic acid, kojic acid, glutathione, and the like, is formulated into a cosmetic such as an ointment or an essence. Whitening was realized or skin hyperpigmentation such as blemishes and freckles was improved. However, hydroquinone exhibits a predetermined whitening effect, but has a problem in that skin irritation is severe and the amount of the compound is limited to a very small amount, and ascorbic acid is easily oxidized, resulting in problems such as discoloration and discoloration. There is this. In addition, thiol-based compounds such as glutathione and cysteine not only have a characteristic unpleasant odor, but also have problems with transdermal absorption, and glycosides and derivatives thereof have high polarity, making it difficult to use as a cosmetic ingredient. Placenta extract, on the other hand, has no irritation to the skin, but lacks a whitening effect.

본 발명은 어피 젤라틴을 특수한 방법으로 가수분해하여 항산화성이 높은 어피 젤라틴 가수분해물 분획과 펩티드를 얻은 바 있고(한국특허공개 96-31582호, 98-34825호), 연구를 계속하여 젤라틴 가수분해물 분획 중에서 특정의 아미노산 서 열을 갖는 펩티드가 특히 멜라닌생성 억제효과가 탁월한 것을 발견하고 본 발명을 완성하기에 이르렀다. The present invention has been obtained by hydrolyzing the fish gelatin in a special method to obtain a high antioxidant antioxidant gelatin hydrolyzate fraction and peptide (Korean Patent Publication No. 96-31582, 98-34825), continuing the study gelatin hydrolyzate fraction Among them, the peptide having a specific amino acid sequence was found to be particularly excellent in inhibiting melanogenesis and came to complete the present invention.

따라서 본 발명의 목적은 상기와 같은 종래의 여러 가지 문제점을 개선시키기 위하여 안출한 것으로, 피부세포내의 과량의 멜라닌 생성을 억제하여 기미, 주근깨 개선 등의 피부미백을 위하여 어류로부터 유래한 멜라닌 생성 억제효과가 탁월한 안전한 젤라틴 펩티드를 유효성분으로 함유하는 연고, 크림, 로션, 화장수, 스프레이, 앰플 등의 조성물을 제조하는 것을 특징으로 하여, 피부에 과량의 멜라닌 축적을 방지하여 피부미백을 제공하는데 그 목적이 있다.Therefore, an object of the present invention is to devise to improve the various problems as described above, inhibiting the production of excess melanin in skin cells to inhibit melanin production from fish for skin whitening such as blemishes, freckles, etc. To prepare a composition such as ointments, creams, lotions, lotions, sprays, ampoules, etc. containing an excellent safe gelatin peptide as an active ingredient, to prevent the accumulation of excessive melanin on the skin to provide a skin whitening have.

본 발명은 세포내의 멜라닌 생성을 억제하여 기미, 주근깨 개선 등의 피부미백을 위하여 어류로부터 유래한 젤라틴 펩티드를 함유하는 화장품 조성물이다. 본 발명에 따른 펩타이드 화합물은 분자 중에 글리신-프롤린-하이드록실프롤린( Glycine-Proline-Hydroxyproline)의 아미노산 서열을 갖고, 아미노산 9~16개로 이루어져 있는 것을 특징으로 하며, 이는 어피 젤라틴을 효소-가수분해한 후, 분자량 1.5 - 4.5 kDa 및 ∼1 kDa 범위내의 가수분해물로부터 분리 정제한 펩타이드 화합물로 피부미백효과가 탁월한 화장품 조성물에 관한 것으로, 연고, 크림, 로션, 화장수, 팩, 산제, 과립제, 정제, 캅셀제 또는 첩포제와 같은 통상적인 제형으로 제조될 수 있다.  The present invention is a cosmetic composition containing gelatin peptides derived from fish for skin whitening such as blemishes, freckles, etc. by inhibiting the production of melanin in the cells. The peptide compound according to the present invention has an amino acid sequence of Glycine-Proline-Hydroxyproline in the molecule, and is characterized by consisting of 9 to 16 amino acids, which is enzyme-hydrolyzed from fish gelatin. The present invention relates to a cosmetic composition having excellent skin whitening effect with a peptide compound separated and purified from a hydrolyzate in the range of 1.5 to 4.5 kDa and a molecular weight of 1 to 1 kDa, and includes an ointment, cream, lotion, lotion, pack, powder, granule, tablet, and capsule. Or in conventional formulations such as patching agents.

본 발명의 구성을, 참조예, 실험예, 실시예 및 비교예, 효과시험예를 통해 설명하면 다음과 같다.Referring to the configuration of the present invention, reference examples, experimental examples, examples and comparative examples, effect test examples are as follows.

[참조예] 젤라틴 펩티드 화합물의 추출방법Reference Example Extraction Method of Gelatin Peptide Compound

본 발명에 따른 항산화성 펩티드는 어피 젤라틴으로부터 얻어진다. 즉, 어피 로부터 젤라틴을 추출해낸 후, 이를 가수분해하여 각종 분자량 범위의 펩티드 혼합물을 얻은 후 이로부터 분리해낼 수 있다.본 발명의 구체적인 예에서는 어피로부터 젤라틴을 얻고, 또 이를 가수분해하는 방법으로서 본 출원인에 의한 한국특허공개 제 96-31582호에 기재된 방법을 이용하였지만, 본 발명에 이러한 특정한 방법에만 국한되는 것은 아니다. 한국특허공개 96-31582호에 기재된 젤라틴 추출법 및 젤라틴의 가수분해법은 본 명세서에도 상세하게 기재되어 있다. 특히 본 발명에서는 참치, 명태, 민태 혹은 오징어의 껍질로부터 열수 추출법에 의해 젤라틴을 추출해내고, 젤라틴을 3단계 막 반응기 장치를 이용하여 효소로 가수분해한 후, 그로부터 멜라닌생성 억제활성이 우수한 펩티드를 분리정제하였다. 젤라틴 가수분해물로 부터 우수한 항산화 활성을 갖는 펩티드를 분리정제하는 것은 통상의 펩티드 분리정제 방법에 따라 실시할 수 있다. The antioxidant peptides according to the invention are obtained from fish gelatin. That is, the gelatine may be extracted from the skin, and then hydrolyzed to obtain a peptide mixture of various molecular weight ranges, and then separated therefrom. In a specific example of the present invention, gelatin is obtained from the skin and hydrolyzed. Although the method described in Korean Patent Publication No. 96-31582 by the applicant was used, the present invention is not limited to this specific method. The gelatin extraction method and the hydrolysis method of gelatin described in Korean Patent Publication No. 96-31582 are also described in detail herein. In particular, in the present invention, gelatin is extracted from the skin of tuna, pollock, minka or squid by hot water extraction, and the gelatine is hydrolyzed with an enzyme using a three-stage membrane reactor, and then a peptide having excellent melanogenesis inhibitory activity is separated therefrom. Purified. Separation and purification of peptides having excellent antioxidant activity from gelatin hydrolyzate can be carried out according to conventional peptide separation and purification methods.

본 발명은, 일련의 크로마토그래피 기술을 이용하여 실시하였는데, 구체적으로는 겔 여과, 이온 교환 및 고속액체 크로마토그래피를 차례로 실시하면서 각 단계별로 각 분획에 대해 멜라닌생성 억제활성을 측정하는 것에 의해 멜라닌생성 억제활성이 특히 우수한 특정의 펩티드를 분리하고, 그의 아미노산 서열을 동정할 수 있었다. 본 발명에 따라 제공되는 항산화성 펩티드는 분자 중에 글리신-프롤린-하이드록실프롤린( Glycine-Proline-Hydroxyproline)의 아미노산 서열을 갖고, 아미 노산 3~20개로 이루어져 있다. 분자중에 포함된 글리신-프롤린-하이드록실프롤린( Glycine-Proline-Hydroxyproline)의 특징적인 서열은 분자 중에 1번 또는 2회 이상 반복하여 존재할 수 있다. 이중에서, 특히 C-말단에 글리신을 갖고 있으며, 아미노산 3~20개로 이루어진 것이다. 본 발명에서 젤라틴의 원료로서 어피를 사용할 수 있으며, 어피는 특히 참치피가 유리하게 사용된다. 이하에는 본 발명에서 이용된 각종 재료물질, 시험방법 등을 상세히 설명한다. The present invention was carried out using a series of chromatographic techniques, specifically, melanogenesis by measuring the melanogenesis inhibitory activity for each fraction at each step while sequentially performing gel filtration, ion exchange and high performance liquid chromatography. The specific peptide which was especially excellent in inhibitory activity was isolate | separated, and the amino acid sequence was identified. The antioxidant peptide provided according to the present invention has an amino acid sequence of Glycine-Proline-Hydroxyproline in the molecule and consists of 3 to 20 amino acids. Characteristic sequences of Glycine-Proline-Hydroxyproline included in a molecule may be present one or more times in the molecule. Among them, in particular the glycine at the C-terminus, consisting of 3 to 20 amino acids. In the present invention, skin can be used as a raw material of gelatin, and in particular, tuna skin is advantageously used. Hereinafter, various materials, test methods, and the like used in the present invention will be described in detail.

본 발명에서 사용된 젤라틴 펩티드화합물의 함량은 0.0001 내지 10 중량%이며, 바람직하게는 0.01 내지 5 중량%이다. 젤라틴 펩티드화합물의 함량이 각각 0.0001 중량% 미만인 농도에서는 멜라닌생성 억제에 대한 효능·효과를 기대할 수 없고 10 중량%를 초과할 경우에는 제품의 안전성의 저하로 부적합하다. 본 발명의 별 불가사리 추출물을 함유한 약제는 멜라닌생성 억제효과 대한 효능을 위하여 어떠한 형태의 약제로도 제조될 수 있으며, 이러한 형태는 연고, 크림, 로션, 화장수, 팩, 산제, 과립제, 정제, 캅셀제 또는 첩포제를 들 수 있다.The content of the gelatin peptide compound used in the present invention is 0.0001 to 10% by weight, preferably 0.01 to 5% by weight. When the content of the gelatin peptide compound is less than 0.0001% by weight, the efficacy and effect of inhibiting melanogenesis cannot be expected. If the content of the gelatin peptide compound exceeds 10% by weight, it is unsuitable for lowering the safety of the product. The drug containing the starfish extract of the present invention can be prepared in any form of the drug for the effect on the melanogenesis inhibitory effect, these forms ointment, cream, lotion, lotion, pack, powder, granules, tablets, capsules Or a patch agent.

이하의 실시예 및 비교예를 통하여 본 발명을 더욱 상세하게 설명한다. 단, 실시예는 본 발명을 예시하기 위한 것이지 이들만으로 한정하는 것이 아니며, 여러 가지로 변형이 가능하다. The present invention will be described in more detail with reference to the following examples and comparative examples. However, the examples are not intended to limit the present invention only to illustrate the invention, and various modifications are possible.

본 발명의 조성물은 멜라닌생성 억제효과를 개선할 목적으로, 토코페롤(Vitamin E), 아스코르빈산(Vitamin C), 쾨르세틴(Quercetin), 루틴(Rutin), 탁시폴린(Taxifolin), 캠프페롤(Kaempferol), 미리세틴(Myricetin), 큐르큐민(Curcumin), 레스베라트롤(Resveratrol), 아레콜린(Arecoline), 아피제 닌(Apigenin), 우고닌(Wogonin), 루테오린(Luteolin) 및 텍토리제닌(Tectorigenin)으로 구성된 군에서 선택되는 1종 이상의 활성산소 생성억제제를 더 함유할 수 있다. 본 발명에서는 이미 정제되어 있는 시그마(Sigma)사 제품을 구입하여 그 중 1종 이상을 선택하여 사용하였다.The composition of the present invention for the purpose of improving the melanogenesis inhibitory effect, tocopherol (Vitamin E), ascorbic acid (Vitamin C), quercetin (Quercetin), Rutin, Taxifolin (Taxifolin), Camperol (Kaempferol) ), Myricetin, Curcumin, Resveratrol, Arecoline, Apigenin, Wogonin, Luteolin and Tectorigenin It may further contain one or more active oxygen production inhibitor selected from the group consisting of). In the present invention, the already purified Sigma (Sigma) company purchased and used at least one of them.

상기 활성산소 생성억제제의 함유량이 너무 적으면 효능을 기대할 수 없고, 너무 많으면 제품의 안전성이 저하되기 때문에, 적절한 함유량은 0.001 내지 5 중량%, 바람직하게는 0.01 내지 3 중량%이다.If the content of the active oxygen generation inhibitor is too small, the efficacy cannot be expected, and if too much, the safety of the product is lowered, so the appropriate content is 0.001 to 5% by weight, preferably 0.01 to 3% by weight.

본 발명의 조성물은 피부 멜라노사이트의 멜라닌 생합성을 억제하는 효과가 탁월한 젤라틴 펩티드화합물을 유효성분으로 함유하는 피부미백 촉진 효과를 갖는 조성물에 관한 것이다.The composition of the present invention relates to a composition having a skin whitening promoting effect containing a gelatin peptide compound having an excellent effect of inhibiting melanin biosynthesis of skin melanocytes as an active ingredient.

본 발명에 따른 젤라틴 펩티드화합물은 피부 멜라노사이트 멜라닌 생합성을 억제하여 피부미백을 촉진하기 위한 어떠한 형태로도 제조될 수가 있다. 이러한 형태의 예를 들면 등 피부를 대상으로 하는 모든 피부용 화장품 조성물에 적용 가능하다. 이들 피부용 화장품 조성물은 당 업계 통상의 방법에 따라 제조할 수 있다.The gelatin peptide compound according to the present invention may be prepared in any form for promoting skin whitening by inhibiting skin melanocyte melanin biosynthesis. In this form, for example, it is applicable to all skin cosmetic compositions for the skin. These cosmetic compositions for skin can be prepared according to methods conventional in the art.

본 발명의 조성물을 제조하여 사람을 대상으로 피부미백 촉진 효과를 평가한 결과 통계적으로 유의적인 효과가 있는 것으로 나타났다.When the composition of the present invention was prepared and evaluated for skin whitening promoting effect in humans, it was found to have a statistically significant effect.

이하, 실시예를 통하여 본 발명을 더욱 상세히 설명한다. 단, 이들 실시예는 본 발명의 예시일 뿐, 본 발명의 범위가 이들만으로 한정되는 것은 아니다. 본 실시예에서 젤라틴 펩티드화합물은 피부미백용 화장품 조성물을 제조하는 것으로 실 험하였지만, 이 역시 본 발명의 예시일 뿐, 본 발명의 기술적 범위가 이들 실시예로만 한정되는 것은 아님은 자명할 것이다.Hereinafter, the present invention will be described in more detail with reference to Examples. However, these Examples are only illustrative of the present invention, and the scope of the present invention is not limited to these. In this embodiment, the gelatin peptide compound has been tested to prepare a cosmetic composition for skin whitening, but this is also merely an example of the present invention, it will be apparent that the technical scope of the present invention is not limited only to these examples.

[실험예 1] 젤라틴 펩티드화합물의 멜라노사이트 세포성장에 대한 효과Experimental Example 1 Effect of Gelatin Peptide Compounds on Melanosite Cell Growth

피부이식시 피부조직을 채취한 다음 미세한 절편으로 피부조직을 자른 후 항생제(50mg/ml gentamicin, 50mg/ml amphotericin, 50U/ml penicillin, 50㎍/streptomycin)을 함유하는 인산완충용액 (Phosphate Buffered Saline)으로 세척하고 0.25% 트립신/이디티에이(Trypsin/EDTA)를 5분동안 처리하여 멜라노사이트 선택배지인 프로모셀회사에서 구입한 M2 배지에서 5% 이산화탄소 및 37℃ 조건의 배양기에서 15일 동안 배양한 후에, 멜라노사이트 세포를 다시 0.25% 트립신/이디티에이(Trypsin/EDTA)로 떼어내어 혈구계수기로 세포수를 세어 M2 배지가 들어 있는 24-웰프레이트(well plate)의 각 well당 1× 104개의 세포가 들어가도록 분주하였다. 세포들이 부착할 수 있도록 1일간 5% 이산화탄소, 100% 습도의 37℃ 배양기에서 배양한 후 대조군에는 식염수를 첨가하고 실험군에는 젤라틴 펩티드화합물을 각각 10, 1, 0.5, 0.1, 0.05, 0.01, 0.005 및 0.001 중량%의 시험 농도로 첨가하고 7일 동안 배양하였다. 각각의 시간이 경과된 후 생리 식염수로 용해한 MTT(3-(4,5-dimethyl- 2-thiazolyl)- 2,5-diphenyl-2H-tetrazolium bromide, Sigma Chemical Co. USA) 용액 300㎕씩을 각각의 well에 첨가하여 4시간 동안 배양하였다. 배양 후 배지를 제거하고 200㎕의 디메틸설폭사이드(DMSO, dimethyl sulfoxide)를 첨가하여 형성된 포마존(formazan) 결정을 용해시킨 후, 세포 활성도를 보기 위해 96-웰프레 이트(well plate)상으로 옮겨서 마이크로프레이트판독기(GENios, TECAN Co., USA)로 540nm에서 흡광도를 측정하였다. 젤라틴 펩티드화합물을 처리하지 않은 군을 대조군의 세포활성을 100%로 하여 실험군과 비교하여 세포활성 효과를 %로 표시하였다.When skin grafts are taken, skin tissues are cut into fine sections and phosphate buffered saline containing antibiotics (50mg / ml gentamicin, 50mg / ml amphotericin, 50U / ml penicillin, 50㎍ / streptomycin). After 5 minutes of treatment with 0.25% Trypsin / EDTA for 5 minutes and incubated for 15 days in an incubator at 5% carbon dioxide and 37 ℃ conditions in M2 medium purchased from the promocel company, melanocyte selection medium Melanocite cells were removed again with 0.25% Trypsin / EDTA and counted with a hemocytometer to count 1 × 10 4 cells in each well of a 24-well plate containing M2 medium. Was busy to enter. The cells were incubated in a 37% incubator at 5% carbon dioxide and 100% humidity for one day, and then saline was added to the control group, and gelatin peptide compounds were added to the experimental group, respectively, 10, 1, 0.5, 0.1, 0.05, 0.01, 0.005 and It was added at a test concentration of 0.001% by weight and incubated for 7 days. After each time, 300 μl of MTT (3- (4,5-dimethyl- 2-thiazolyl) -2,5-diphenyl-2H-tetrazolium bromide, Sigma Chemical Co. USA) solution dissolved in physiological saline solution It was added to the wells and incubated for 4 hours. After incubation, the medium was removed and 200 μl of dimethyl sulfoxide (DMSO) was added to dissolve the formazan crystals, which were then transferred onto a 96-well plate for cell activity. Absorbance was measured at 540 nm with a microplate reader (GENios, TECAN Co., USA). In the group not treated with the gelatin peptide compound, the cell activity of the control group was 100%, and the cell activity effect was expressed in% compared with the experimental group.

표 1. 젤라틴 펩티드화합물의 함량에 따른 세포활성도가 증가 비교표Table 1. Comparison of increase in cell activity according to the content of gelatin peptide compound

Figure 112006043679717-pat00001
Figure 112006043679717-pat00001

위 표1에서 나타난 바와 같이 젤라틴 펩티드화합물은 멜라노사이트의 세포독성에 어떠한 해로운 효과도 없는 것으로 나타났다. As shown in Table 1 above, the gelatin peptide compound was found to have no detrimental effect on the cytotoxicity of melanocytes.

[실험예 2] 피부 멜라노사이트에서 젤라틴 펩티드화합물의 멜라닌 생합성 억제 효과Experimental Example 2 Inhibitory Effect of Gelatin Peptide Compounds on Melanin Biosynthesis in Skin Melanosite

피부이식시 피부조직을 채취한 다음 미세한 절편으로 피부조직을 자른 후, 항생제(50mg/ml gentamicin, 50mg/ml amphotericin, 50U/ml penicillin, 50㎍/streptomycin)을 함유하는 인산완충용액 (PhosphateBufferedSaline)으로 세척하고 0.25% Trypsin/EDTA를 5분동안 처리하여 멜라노사이트 선택배지인 M2 배지 (Promocell)에서 5% CO2 및 37℃ 조건의 배양기에서 15일동안 배양한 후에, 멜라노사이트 세포를 다시 0.25% Trypsin/EDTA로 떼어내어 혈구계수기로 세포수를 세어 M2 배지(Promocell)가 들어 있는 24-well 에 well당1× 104개로 접종한후 37℃에서 포가 well 닥에 80%d이상 부착될 때까지 배양한다. 1일 배양후 멜라닌 색소의 전 구체인 도파를 0.08mM 되게 첨가한 다음 젤라틴 펩티드화합물을 각각 10, 1, 0.5, 0.1, 0.05, 0.01, 0.005 및 0.001 중량%의 시험 농도로 첨가하고 3일 동안 배양하여 대조군에는 식염수를 넣었다. 배지를 제거한 세포를 인산완충용액(PBS, PhosphateBufferedSaline)세척하고, 이것을 트립신으로 처리하여 세포를 회수한다. 회수된세포는 헤마토사이토메터(Hematocytometer)를 이용하여 세포수를 측정한 후 5,000내지 10,000으로 10분간 원심분리한 다음 상등액을 제거하여 침전물을 얻는다.이 세포침전물은 60℃에서 건조한 후 10%가 함유된 1M수산화나트륨액 100㎕를 넣어 60℃ 항온조에서 세포내 멜라닌을 얻는다. 이 액을 가지고 마이크로프레이트(Microplate)로 490에서흡광도를 측정하여 세포수당 멜라닌함량을 젤라틴 펩티드화합물을 처리하지 않은 대조군과 실험군을 비교하여 %로 표시하였다.After skin graft, skin tissue was collected and cut into fine sections, followed by phosphate buffered saline containing antibiotics (50mg / ml gentamicin, 50mg / ml amphotericin, 50U / ml penicillin, 50㎍ / streptomycin). After washing and incubating with 0.25% Trypsin / EDTA for 5 minutes and incubating for 15 days in an incubator at 37 ° C. with 5% CO2 in melanocyte selective medium M2 medium (Promocell), the melanocytes were again 0.25% Trypsin / Remove the cells with EDTA, count the cells with a hemocytometer, inoculate 1 × 10 4 cells per well in 24-well containing M2 medium (Promocell), and incubate at 37 ° C until more than 80% d of the pore well is attached. . After 1 day of incubation, dopa, a precursor of melanin pigment, was added to 0.08 mM, and then the gelatin peptide compound was added at test concentrations of 10, 1, 0.5, 0.1, 0.05, 0.01, 0.005 and 0.001% by weight, respectively, and cultured for 3 days. Saline was added to the control group. The cells from which the medium has been removed are washed with phosphate buffered solution (PBS) and treated with trypsin to recover the cells. The recovered cells were measured by using a hematocytometer, and then centrifuged at 5,000 to 10,000 for 10 minutes, and then the supernatant was removed to obtain a precipitate. 100 μl of 1 M sodium hydroxide solution was added to obtain intracellular melanin in a 60 ° C. thermostat. Using this solution, the absorbance was measured at 490 using a microplate, and the melanin content per cell number was expressed in% compared to the control group without treatment with the gelatin peptide compound.

표 2. 젤라틴 펩티드화합물별의 함량에 따른 멜라닌 생합성이 촉진 비교표 Table 2. Comparative Table for Promoting Melanin Biosynthesis According to Gelatin Peptide Compound Contents

Figure 112006043679717-pat00002
Figure 112006043679717-pat00002

위 표 2에서 보듯이, 젤라틴 펩티드화합물 함량이 증가함에 따라 멜라노사이트의 멜라닌 생합성이 억제되는 것으로 나타났다. As shown in Table 2, the melanin biosynthesis of melanocytes was suppressed as the gelatin peptide compound content increased.

[실험예 3] 동물에서 젤라틴 펩티드화합물의 미백효과Experimental Example 3 Whitening Effect of Gelatin Peptide Compound in Animals

체중량이 400g 전후의 브라운니쉬 기니픽을 10마리씩 7개의 시험군과 1개의 대조군으로 나누어 등부위를 탈모한 후, 피부에 3× 3cm의 정방형의 물질도포 자리 두 곳을 표시한다. 이 때, 한 곳은 본 발명의 젤라틴 펩티드화합물을 도포할 자리 이며, 한 곳은 대조부위이다. l일 1회 또는 2회의 횟수로 도포하며, 이를 30일간 계속하였다. 비교를 위해 대조부위에는 누적자극이 나타나지 않는 대조군(프로필렌글리콜:에탄올: 정제수=5:3:2의 혼합용매)을 면봉으로 도포하고 실험군은 별 불가사리 추출물을 용매에 0.01 내지 1중량%로 용해하여 상기 실험군도포자리에 0.1ml를 매일 2회면봉으로 도포하였다. 최소홍반량의 자외선을 1일 1회, 총 3회 조사하였다. 1개월후, 색소 침착의 판정기준은 각각의 화합물의 처리군을 대조군 (4점)과 비교하여 색소면적 0 ~ 25% (1점), 26 ~ 50% (2점), 51 ~ 75% (3점), 76 ~ 100%(1점)의 4단계로 동물수를 판정하였으며, 그 결과는 표 3과 같다. 10 Brownish guinea pigs weighing about 400g were divided into 7 test groups and 1 control group, each with hair loss at the back, and the skin was marked with two 3 × 3 cm square material spots. At this time, one place is to apply the gelatin peptide compound of the present invention, and one place is the control site. Apply once or twice a day, and continue for 30 days. For comparison, a control group (propylene solvent: ethanol: purified water = 5: 3: 2 mixed solvent) with no cumulative stimulus was applied to the control area with a cotton swab, and the experimental group dissolved starfish extract in a solvent at 0.01 to 1% by weight. 0.1ml was applied to the experimental group application site twice with a cotton swab every day. Ultraviolet rays of the minimum amount of erythema were irradiated three times a day. After 1 month, the criterion for pigmentation was 0-25% (1 point), 26-50% (2 points), 51-75% (pigment area) of the treated groups of each compound compared to the control group (4 points). 3 points), 76 ~ 100% (1 point) was determined by the number of animals in four stages, the results are shown in Table 3.

표 3. 동물에서 젤라틴 펩티드화합물의 미백효과 비교표Table 3. Comparison of Whitening Effect of Gelatin Peptide Compounds in Animals

Figure 112006043679717-pat00003
Figure 112006043679717-pat00003

표 3의 결과에서 알 수 있듯이, 젤라틴 펩티드화합물은 자외선 A로 유발된 브라운니쉬 기니픽의 멜라닌 생성 억제효과가 가 있음이 확인되었고, 아스코르빈산을 병용하여 처리시 단독사용시보다 미백효과에 대한 상승효과가 있는 것으로 나 타났다.As can be seen from the results of Table 3, it was confirmed that the gelatine peptide compound had an inhibitory effect on melanin production of brownish guinea pigs induced by UVA, and a synergistic effect on the whitening effect when treated with ascorbic acid alone. Appeared to be.

[실시예 1 내지 비교예 1] 연고의 제조Example 1 to Comparative Example 1 Preparation of Ointment

젤라틴 펩티드화합물은 0.01%, 디에틸세바케이트 8.0%, 경납 5.0%, 폴리옥시에틸렌올레일-에테르 포스페이트(EO 4) 6.0%, 파라옥시안식향산에스테르 적량, 바세린 잔량으로 통상의 연고제조방법에 따라 제조한다. 비교예는 이 조성물에 젤라틴 펩티드화합물을 제외시켰다.Gelatin peptide compound is prepared according to the conventional ointment manufacturing method in 0.01%, diethyl sebacate 8.0%, light lead 5.0%, polyoxyethylene oleyl-ether phosphate (EO 4) 6.0%, a suitable amount of paraoxybenzoic acid ester, residual amount of petrolatum. do. Comparative Example excludes gelatin peptide compounds from this composition.

[실시예 2 내지 비교예 2 ] 유연화장수의 제조Example 2 to Comparative Example 2 Preparation of Soft Cosmetics

젤라틴 펩티드화합물 0.1%, 글리세린 2.0%, 히알루론산 1.0%, 폴리옥시에틸렌올레일에테르 (EO20) 0.1%, 폴리옥시에틸렌경화피마자유(EO40) 0.1%, 파라옥시안식향산에스테르 적량, 향료 적량, 색소 적량, 정제수 잔량으로 통상의 유연화장수 제조방법에 따라 제조한다. 비교예는 이 조성물에 젤라틴 펩티드화합물을 제외시켰다.Gelatin Peptide Compound 0.1%, Glycerin 2.0%, Hyaluronic Acid 1.0%, Polyoxyethylene Oleyl Ether (EO20) 0.1%, Polyoxyethylene Cured Castor Oil (EO40) 0.1%, Paraoxybenzoic Acid Ester Amount, Flavor Amount, Pigment Amount In the remaining amount of purified water, it is prepared according to a conventional flexible cosmetic preparation method. Comparative Example excludes gelatin peptide compounds from this composition.

[실시예 3 내지 비교예 3 ] 영양유액의 제조Example 3 to Comparative Example 3 Preparation of Nutrients

젤라틴 펩티드화합물 1%, 세탄올 1.0%, 밀납 0.5%, 바세린 2.0%, 스쿠알란 6.0%, 에탄올 3.0%, 1,3-부틸렌글리콜 4.0%, 폴리솔베이트60 1.0%, 솔비탄 세스퀴 올레이트 0.3%, 카르복시 비닐폴리머 0.3%, 트리에탄올아민 0.3%, 파라옥시안식향산에스테르 적량, 향료 적량, 색소 적량, 정제수 잔량으로 통상의 영양유액 제조방법에 따라 제조한다. 비교예는 이 조성물에 젤라틴 펩티드화합물을 제외시켰다.Gelatin Peptide Compound 1%, Cetanol 1.0%, Beeswax 0.5%, Vaseline 2.0%, Squalane 6.0%, Ethanol 3.0%, 1,3-Butylene Glycol 4.0%, Polysorbate 60 1.0%, Solbitan Sesquioleate 0.3%, carboxy vinyl polymer 0.3%, triethanolamine 0.3%, the amount of paraoxybenzoic acid ester, the amount of perfume, the amount of pigment, the amount of purified water is prepared according to the conventional nutrient emulsion production method. Comparative Example excludes gelatin peptide compounds from this composition.

[실시예 4 내지 비교예 4 ] 크림의 제조Example 4 to Comparative Example 4 Preparation of Cream

젤라틴 펩티드화합물 0.01%, 아스코르빈산 0.01%, 스테아린산 2.0%, 농글리 세린 1.0%, 스쿠알란 9.0%, 1,3-부틸렌글리콜6.0%, 폴리솔베이트60 1.5%, 폴리에틸렌글리콜1000 4.0%, 경화 라놀린 4.0%, 옥틸 도데카놀 10.0%, 솔비탄 스테아레이트 0.8%, 트리에탄올아민 0.5%, 파라옥시안식향산에스테르 적량, 향료 적량, 색소 적량, 정제수 잔량으로 통상의 크림 제조방법에 따라 제조한다. 비교예는 이 조성물에 젤라틴 펩티드화합물을 제외시켰다.Gelatin Peptide Compound 0.01%, Ascorbic Acid 0.01%, Stearic Acid 2.0%, Nong glycerin 1.0%, Squalane 9.0%, 1,3-butylene glycol 6.0%, Polysorbate 60 1.5%, Polyethylene glycol 1000 4.0%, Curing Lanolin 4.0%, octyl dodecanol 10.0%, sorbitan stearate 0.8%, triethanolamine 0.5%, the amount of paraoxybenzoic acid ester, the amount of perfume, the amount of pigment, the amount of purified water according to the conventional cream preparation method. Comparative Example excludes gelatin peptide compounds from this composition.

[실시예 5 내지 비교예 5 ] 에센스의 제조Example 5 to Comparative Example 5 Preparation of Essence

사이클로메티콘 15.0%, 카프릴릭카프릭트리글리세라이드 3.0%, 미네랄오일 3.0%, 밀납 1.0%, 세틸디메티콘코폴리올 3.0%, 젤라틴 펩티드화합물 0.1%, 0.01%, 아스코르빈산, 글리세린 5.0%, 황산마그네슘 3.0%, 파라옥시안식향산에스테르 적량, 향료 적량, 색소 적량, 정제수 잔량으로 통상의 에센스 제조방법에 따라 제조한다. 비교예는 이 조성물에 젤라틴 펩티드화합물을 제외시켰다.Cyclomethicone 15.0%, Caprylic Capric Triglyceride 3.0%, Mineral Oil 3.0%, Beeswax 1.0%, Cetyl Dimethicone Copolyol 3.0%, Gelatin Peptide Compound 0.1%, 0.01%, Ascorbic Acid, Glycerin 5.0%, Sulfuric Acid Magnesium 3.0%, paraoxybenzoic acid ester amount, perfume amount, pigment amount, purified water residual amount is prepared according to a conventional essence production method. Comparative Example excludes gelatin peptide compounds from this composition.

[실험예 4] 사람에서 비교예 및 실시예 및 1내지 5의 미백효과Experimental Example 4 Whitening Effect of Comparative Examples and Examples and 1 to 5 in Humans

피부에 멜라닌으로 고민하는 40대 내지 50대의 건강한 여성 및 남성 대상으로 실시예 각 본 발명 조성물당 임의로 10명씩 합계 100명을 선정하고, 얼굴을 세로로 2등분하여,왼쪽볼에는 실시예 1내지 5의 본발명 조성물을, 오른쪽 볼에는 비교예 1내지5의 대조군을 아침, 저녁으로 하루에 2회씩,2달간 적용하게 하였다. 미백효과의 판정은 본 발명 조성물을 사용한 후, 피험자 개인의 주관적 평가로 하기의 평가점수를 통해 미백효과 정도를 평가하도록 하였다. 그 결과는 하기 표 7에 나타내었다. Example for healthy women and men in their 40s and 50s who suffer from melanin on the skin, 100 randomly selected total 10 persons per each composition of the present invention, the face is divided into two vertically, Examples 1 to 5 on the left cheek The present invention composition of the right side, the control of Comparative Examples 1 to 5 was applied twice a day, morning and evening, for two months. Determination of the whitening effect was to evaluate the degree of whitening effect through the following evaluation score by subjective evaluation of the individual after using the composition of the present invention. The results are shown in Table 7 below.

표 7. 사람에서 백발생성 억제 및 흑모 촉진 효과 평가표Table 7. Evaluation table for the effect of suppressing white development and promoting black hair in human

Figure 112006043679717-pat00004
Figure 112006043679717-pat00004

(평가점수)(Score)

3 : 미백효과가 대조군에 비하여 75% 이상 우수함 3: The whitening effect is more than 75% better than the control group

2 : 미백효과가 대조군에 비하여 50 ~ 75% 우수함2: Whitening effect is 50 ~ 75% superior to the control group

1 : 미백효과가 대조군에 비하여 25 ~ 50% 우수함 1: Whitening effect is 25 ~ 50% better than the control group

0 : 미백효과가 대조군에 비하여 25% 이하임.0: whitening effect is 25% or less than the control group.

본 발명의 조성물이 연고, 유연화장수, 영양유액, 크림 또는 에센스 등의 화장용 조성물로 사용되었을 때, 이상의 실험 결과에서 보듯이, 젤라틴 펩티드 화합물을 함유하는 실시예 1 내지 5의 화장용 조성물은 모두 비교예 1 내지 5와 비교하여 미백효과가 탁월하였고, 또한 젤라틴 펩티드 화합물을의 함량이 증가함에 따라 그리고 아스코르빈산과 병용시 미백효과가 증가하는 것으로 나타났다.When the composition of the present invention is used in cosmetic compositions such as ointment, softening water, nutrient emulsion, cream or essence, as shown in the above experimental results, all of the cosmetic compositions of Examples 1 to 5 containing a gelatin peptide compound Compared with Comparative Examples 1 to 5, the whitening effect was excellent, and the whitening effect was increased with increasing content of the gelatin peptide compound and when used with ascorbic acid.

이상에서와 같이 본 발명은 비록 상기의 실시예에 한하여 설명하였지만 반드시 여기에만 한정되는 것은 아니며 본 발명의 범주와 사상을 벗어나지 않는 범위 내에서 다양한 변형실시가 가능함은 물론이다.As described above, although the present invention has been described with reference to the above embodiments, it is not necessarily limited thereto, and various modifications may be made without departing from the scope and spirit of the present invention.

이상에서 보여준 바와 같이 젤라틴 펩티드 화합물은 사람의 멜라노사이트의 멜라닌 생합성 억제효과가 탁월하여, 스킨, 로션, 크림, 파운데이션, 에센스, 젤, 팩, 폼 클렌징, 비누와 같은 화장료, 피부외용 연고와 같은 약품 등의 피부미백용 조성물에 첨가하면 별다른 부작용 없이 강력한 피부 미백효과를 나타낼 수 있다.As shown above, the gelatine peptide compound is excellent in inhibiting melanin biosynthesis of human melanocytes, such as skins, lotions, creams, foundations, essences, gels, packs, foam cleansing, cosmetics such as soaps, and cosmetics such as skin ointments. When added to such a composition for skin whitening, it can exhibit a powerful skin whitening effect without any side effects.

Claims (6)

멜라닌 생성 억제 화장용 조성물에 있어서, In the composition for inhibiting melanin production, 글리신-프롤린-하이드록실프롤린(Glycine-Proline-Hydroxyproline)의 아미노산 서열을 갖고, 아미노산 3~20개로 이루어져 있는 젤라틴 펩티드 화합물을 함유하는 것을 특징으로 하는 피부미백용 조성물.A composition for skin whitening having an amino acid sequence of glycine-proline-hydroxyproline and containing a gelatin peptide compound consisting of 3 to 20 amino acids. 삭제delete 제 1항에 있어서, 젤라틴 펩티드 화합물은 탄소사슬(C)-말단에 글리신 ( Glycine)을 갖고 있으며, 아미노산 3~20개로 이루어진 것을 특징으로 하는 피부미백용 조성물.The composition of claim 1, wherein the gelatin peptide compound has glycine (Glycine) at the carbon chain (C) -terminus and consists of 3 to 20 amino acids. 제 1항에 있어서, 젤라틴 펩티드 화합물은 조성물 전체 중량에 대하여 0.001 내지 10 중량% 함유하는 것을 특징으로 하는 피부미백용 조성물.The composition for skin whitening according to claim 1, wherein the gelatin peptide compound contains 0.001 to 10% by weight based on the total weight of the composition. 제 1항에 있어서, 피부미백용 조성물은 쾨르세틴(Quercetin), 루틴(Rutin), 탁시폴린(Taxifolin), 캠프페롤(Kaempferol), 미리세틴(Myricetin), 큐르큐민(Curcumin), 레스베라트롤 (Resveratrol), 아레콜린(Arecoline), 아피제닌(Apigenin), 우고닌(Wogonin), 루테오린(Luteolin) 및 텍토리제닌(Tectorigenin) 으로 구성된 군에서 선택되는 1종 이상의 활성산소 생성억제제를 조성물 전체 중량에 대하여 0.001 내지 5 중량%를 추가로 함유하는 것을 특징으로 하는 피부미백용 조성물.The composition of claim 1, wherein the composition for skin whitening is Quercetin, Rutin, Taxifolin, Kaempferol, Myricetin, Curcumin, Resveratrol At least one active oxygen-producing inhibitor selected from the group consisting of arecoline, apigenin, apigenin, wogonin, luteolin and tetorigenin Skin whitening composition, characterized in that it further comprises 0.001 to 5% by weight. 제 1항에 있어서, 피부미백용 조성물은 스킨, 로션, 크림, 파운데이션, 에센스, 젤, 팩, 폼 클렌징, 비누와 같은 화장료, 피부외용 연고와 같은 약품 연고, 크림, 로션, 화장수용 조성물을 포함하는 것을 특징으로 하는 피부미백용 조성물.The composition of claim 1, wherein the composition for skin whitening comprises skin, lotion, cream, foundation, essence, gel, pack, foam cleansing, cosmetic such as soap, pharmaceutical ointment such as external skin ointment, cream, lotion, cosmetic composition Skin whitening composition, characterized in that.
KR1020060055757A 2006-06-21 2006-06-21 Melanin production inhibitory skin whitening cosmetic composition Expired - Fee Related KR100760875B1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR1020060055757A KR100760875B1 (en) 2006-06-21 2006-06-21 Melanin production inhibitory skin whitening cosmetic composition

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
KR1020060055757A KR100760875B1 (en) 2006-06-21 2006-06-21 Melanin production inhibitory skin whitening cosmetic composition

Publications (1)

Publication Number Publication Date
KR100760875B1 true KR100760875B1 (en) 2007-10-04

Family

ID=39418561

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020060055757A Expired - Fee Related KR100760875B1 (en) 2006-06-21 2006-06-21 Melanin production inhibitory skin whitening cosmetic composition

Country Status (1)

Country Link
KR (1) KR100760875B1 (en)

Cited By (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010053340A3 (en) * 2008-11-10 2010-07-08 주식회사 알엔에스 Skin-whitening composition
KR101221711B1 (en) 2010-09-17 2013-01-11 제주대학교 산학협력단 Cosmetic composition containing extract of Cleyera japonica
WO2014109519A1 (en) * 2013-01-10 2014-07-17 강원대학교산학협력단 Microphthalmia-associated transcription factor-derived peptide and composition containing same
KR101515158B1 (en) 2013-01-30 2015-04-24 (주)에스테위즈 Cosmetic composition containing disulfanyl hypopigmenting peptide
EP2444061A4 (en) * 2009-06-17 2015-08-05 Kao Corp Apigenin-containing composition
KR20150109940A (en) 2014-03-21 2015-10-02 서울대학교병원 (분사무소) Antioxidant composition containing ACQ
KR101569772B1 (en) 2014-01-08 2015-11-17 주식회사 엘지생활건강 Anti-dark circle composition comprising wogonin or pharmaceutically acceptable salts thereof
KR20160008123A (en) 2015-12-09 2016-01-21 서울대학교병원 (분사무소) Composition with Antioxidation Function Containing ACQ
KR102038697B1 (en) * 2019-05-08 2019-10-30 주식회사 앱타이론바이오 Cosmetic Composition for Anti-oxidation and Whitening of Skin
KR20190136230A (en) 2018-05-30 2019-12-10 주식회사 헬리오스 Cosmetic compostion using barley malt
JP2020147501A (en) * 2019-03-11 2020-09-17 株式会社関門海 Side effect reducing agent for anticancer agent

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2000309521A (en) * 1999-02-23 2000-11-07 Shiseido Co Ltd Skin lotion

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2000309521A (en) * 1999-02-23 2000-11-07 Shiseido Co Ltd Skin lotion

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
일본공개특허공보 특개2000-309521

Cited By (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010053340A3 (en) * 2008-11-10 2010-07-08 주식회사 알엔에스 Skin-whitening composition
EP2444061A4 (en) * 2009-06-17 2015-08-05 Kao Corp Apigenin-containing composition
KR101221711B1 (en) 2010-09-17 2013-01-11 제주대학교 산학협력단 Cosmetic composition containing extract of Cleyera japonica
WO2014109519A1 (en) * 2013-01-10 2014-07-17 강원대학교산학협력단 Microphthalmia-associated transcription factor-derived peptide and composition containing same
US9493528B2 (en) 2013-01-10 2016-11-15 Supadelixir Inc. Microphthalmia-associated transcription factor-derived peptide and composition containing same
KR101515158B1 (en) 2013-01-30 2015-04-24 (주)에스테위즈 Cosmetic composition containing disulfanyl hypopigmenting peptide
KR101569772B1 (en) 2014-01-08 2015-11-17 주식회사 엘지생활건강 Anti-dark circle composition comprising wogonin or pharmaceutically acceptable salts thereof
KR20150109940A (en) 2014-03-21 2015-10-02 서울대학교병원 (분사무소) Antioxidant composition containing ACQ
KR20160008123A (en) 2015-12-09 2016-01-21 서울대학교병원 (분사무소) Composition with Antioxidation Function Containing ACQ
KR20190136230A (en) 2018-05-30 2019-12-10 주식회사 헬리오스 Cosmetic compostion using barley malt
JP2020147501A (en) * 2019-03-11 2020-09-17 株式会社関門海 Side effect reducing agent for anticancer agent
JP7338835B2 (en) 2019-03-11 2023-09-05 株式会社関門海 Anti-cancer agent for reducing side effects
KR102038697B1 (en) * 2019-05-08 2019-10-30 주식회사 앱타이론바이오 Cosmetic Composition for Anti-oxidation and Whitening of Skin

Similar Documents

Publication Publication Date Title
KR100760875B1 (en) Melanin production inhibitory skin whitening cosmetic composition
US11752168B2 (en) Methods of using cosmetic compositions comprising exopolysaccharides derived from microbial mats
JP5346339B2 (en) Wrinkle improving and moisturizing composition and cosmetics
KR101390061B1 (en) Para-Coumaric Acid or para-Hydroxycinnamic Acid Derivatives and Their Use in Cosmetic or Dermatological Compositions
KR101081914B1 (en) Skin-care agent containing oriental-herb extracts
KR101081913B1 (en) Skin agent composition containing the oriental-herb extracts using microbial fermentation
KR100825450B1 (en) Cosmetic composition for improving skin wrinkles containing duct extract
JP2020532560A (en) Cosmetic composition containing extract of Dendrobium candidam flower
CN111201012A (en) Cosmetic composition for skin whitening and wrinkle improvement containing Centella asiatica adventitious root extract as an active ingredient
KR101436199B1 (en) Composition for Improving Skin Conditions Comprising Hordenine
KR102193209B1 (en) Cosmetic composition for skin whitening comprising extract of Phragmites Communis
EP2305212A1 (en) Composition comprising one extract of at least one filamentous bacterium and process for treating signs of ageing thereof
KR20210090790A (en) Melanin production inhibitory skin whitening cosmetic composition
JP3557095B2 (en) Melanin production inhibitor
KR101863297B1 (en) Composition for preventing or improving skin wrinkle comprising chlorogenic acid and rutin compound as active ingredient
KR101180258B1 (en) A skin-care agent containing Ophioglossum vulgatum extracts using microbial fermentation
KR20100018139A (en) A skin-care agent containing sedum sarmentosum extracts and lipoic acid-peg conjugated compounds
KR20140097865A (en) Cosmetic composition comprising Laver extract for anti-inflammation
JPH0987164A (en) Skin preparation for external use
KR100710657B1 (en) Whitening cosmetic composition containing dihydroquecetin
JP4956164B2 (en) Melanin transport and / or release inhibitor
KR101686521B1 (en) Composition for beauty of skin
KR20130089559A (en) Anti-aging composition
KR20160132151A (en) Skin agent composition
KR102526200B1 (en) Composition for Skin Moisturizing and Whitening Comprising Decurcinol as Active Ingredient

Legal Events

Date Code Title Description
A201 Request for examination
PA0109 Patent application

St.27 status event code: A-0-1-A10-A12-nap-PA0109

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

D13-X000 Search requested

St.27 status event code: A-1-2-D10-D13-srh-X000

D14-X000 Search report completed

St.27 status event code: A-1-2-D10-D14-srh-X000

PN2301 Change of applicant

St.27 status event code: A-3-3-R10-R11-asn-PN2301

St.27 status event code: A-3-3-R10-R13-asn-PN2301

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
GRNT Written decision to grant
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

Fee payment year number: 1

St.27 status event code: A-2-2-U10-U11-oth-PR1002

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

PR1001 Payment of annual fee

Fee payment year number: 4

St.27 status event code: A-4-4-U10-U11-oth-PR1001

FPAY Annual fee payment

Payment date: 20110902

Year of fee payment: 5

PR1001 Payment of annual fee

Fee payment year number: 5

St.27 status event code: A-4-4-U10-U11-oth-PR1001

FPAY Annual fee payment

Payment date: 20121130

Year of fee payment: 6

PR1001 Payment of annual fee

Fee payment year number: 6

St.27 status event code: A-4-4-U10-U11-oth-PR1001

LAPS Lapse due to unpaid annual fee
PC1903 Unpaid annual fee

Not in force date: 20130918

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

St.27 status event code: A-4-4-U10-U13-oth-PC1903

PC1903 Unpaid annual fee

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20130918

St.27 status event code: N-4-6-H10-H13-oth-PC1903

P22-X000 Classification modified

St.27 status event code: A-4-4-P10-P22-nap-X000

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000

PN2301 Change of applicant

St.27 status event code: A-5-5-R10-R11-asn-PN2301

St.27 status event code: A-5-5-R10-R13-asn-PN2301

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000

PN2301 Change of applicant

St.27 status event code: A-5-5-R10-R11-asn-PN2301

St.27 status event code: A-5-5-R10-R13-asn-PN2301

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000

PN2301 Change of applicant

St.27 status event code: A-5-5-R10-R11-asn-PN2301

St.27 status event code: A-5-5-R10-R13-asn-PN2301

PN2301 Change of applicant

St.27 status event code: A-5-5-R10-R11-asn-PN2301

St.27 status event code: A-5-5-R10-R13-asn-PN2301

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000